;PMID: 2115851
;source_file_860.mrg
;Release 0.9 of PennBioIE
;Funded by NSF ITR EIA-0205448

;0)section:[e:0..46] = [t:0..46]
;1)sentence:[e:52..177] = [t:52..177]
;2)section:[e:181..207] = [t:181..207]
;3)section:[e:211..307] = [t:211..307]
;4)sentence:[e:311..493] = [t:311..493]
;5)sentence:[e:494..669] = [t:494..669]
;6)sentence:[e:670..798] = [t:670..798]
;7)sentence:[e:799..916] = [t:799..916]
;8)sentence:[e:917..1038] = [t:917..1038]
;9)sentence:[e:1039..1175] = [t:1039..1175]
;10)sentence:[e:1176..1397] = [t:1176..1397]
;11)sentence:[e:1398..1628] = [t:1398..1628]
;12)section:[e:1632..1676] = [t:1632..1675]
;Sentence Matching Errors
;ERROR_Section end mismatch[e:1632..1676][t:1632..1675]
;Token/POS Errors
;ERROR_Token in entity file but not tree[1675..1676] ]

;section 0 Span:0..46
;Mol Cell Endocrinol. 1990 Jun 18;71(2):133-40.
(SEC
  (FRAG (NNP:[0..3] Mol) (NNP:[4..8] Cell) (NNP:[9..19] Endocrinol)
        (.:[19..20] .) (CD:[21..25] 1990) (NNP:[26..29] Jun) (CC:[30..32] 18)
        (::[32..33] ;) (CD:[33..35] 71) (-LRB-:[35..36] -LRB-) (CD:[36..37] 2)
        (-RRB-:[37..38] -RRB-) (::[38..39] :) (CD:[39..42] 133)
        (HYPH:[42..43] -) (CD:[43..45] 40) (.:[45..46] .)))

;sentence 1 Span:52..177
;Cellular distribution of prostacyclin synthase and specific prostacyclin
;binding  sites in bovine corpora lutea of pregnancy.
;[77..98]:cyp450:"prostacyclin synthase"
;[112..124]:substance:"prostacyclin"
(SENT
  (NP-HLN
    (NP (JJ:[52..60] Cellular) (NN:[61..73] distribution))
    (PP (IN:[74..76] of)
      (NP
        (NP (NN:[77..89] prostacyclin) (NN:[90..98] synthase))
        (CC:[99..102] and)
        (NP (JJ:[103..111] specific) (NN:[112..124] prostacyclin)
            (NN:[125..132] binding) (NNS:[134..139] sites))))
    (PP-LOC (IN:[140..142] in)
      (NP
        (NP (JJ:[143..149] bovine) (FW:[150..157] corpora) (FW:[158..163] lutea))
        (PP (IN:[164..166] of)
          (NP (NN:[167..176] pregnancy)))))
    (.:[176..177] .)))

;section 2 Span:181..207
;Chegini N, Lei ZM, Rao CV.
(SEC
  (FRAG (NNP:[181..188] Chegini) (NNP:[189..190] N) (,:[190..191] ,)
        (NNP:[192..195] Lei) (NNP:[196..198] ZM) (,:[198..199] ,)
        (NNP:[200..203] Rao) (NNP:[204..206] CV) (.:[206..207] .)))

;section 3 Span:211..307
;Department of Obstetrics and Gynecology, University of Louisville School of 
;Medicine, KY 40292.
(SEC
  (FRAG (NNP:[211..221] Department) (IN:[222..224] of)
        (NNP:[225..235] Obstetrics) (CC:[236..239] and)
        (NNP:[240..250] Gynecology) (,:[250..251] ,) (NNP:[252..262] University)
        (IN:[263..265] of) (NNP:[266..276] Louisville) (NNP:[277..283] School)
        (IN:[284..286] of) (NNP:[288..296] Medicine) (,:[296..297] ,)
        (NNP:[298..300] KY) (CD:[301..306] 40292) (.:[306..307] .)))

;sentence 4 Span:311..493
;The cellular distribution of prostacyclin (PGI2) synthase and specific PGI2 
;binding sites was investigated by light microscope immunocytochemistry and 
;quantitative autoradiography.
;[340..368]:cyp450:"prostacyclin (PGI2) synthase"
;[382..386]:substance:"PGI2"
(SENT
  (S
    (NP-SBJ-1
      (NP (DT:[311..314] The) (JJ:[315..323] cellular)
          (NN:[324..336] distribution))
      (PP (IN:[337..339] of)
        (NP
          (NP
            (NML
              (NML (NN:[340..352] prostacyclin))
              (NML (-LRB-:[353..354] -LRB-) (NN:[354..358] PGI2)
                   (-RRB-:[358..359] -RRB-)))
            (NN:[360..368] synthase))
          (CC:[369..372] and)
          (NP (JJ:[373..381] specific) (NN:[382..386] PGI2)
              (NN:[388..395] binding) (NNS:[396..401] sites)))))
    (VP (VBD:[402..405] was)
      (VP (VBN:[406..418] investigated)
        (NP-1 (-NONE-:[418..418] *))
        (PP-MNR (IN:[419..421] by)
          (NP
            (NP (NN:[422..427] light) (NN:[428..438] microscope)
                (NN:[439..458] immunocytochemistry))
            (CC:[459..462] and)
            (NP (JJ:[464..476] quantitative) (NN:[477..492] autoradiography))))))
    (.:[492..493] .)))

;sentence 5 Span:494..669
;The immunostaining for the enzyme was found in  small (15-18 microns) and
;large (18-45 microns) cells as well as in non-luteal  cells, arteriole smooth
;muscle and endothelium.
;[521..527]:substance:"enzyme"
;[549..554]:quantitative-value:"15-18"
;[555..562]:quantitative-units:"microns"
;[575..580]:quantitative-value:"18-45"
;[581..588]:quantitative-units:"microns"
(SENT
  (S
    (NP-SBJ-4
      (NP (DT:[494..497] The) (NN:[498..512] immunostaining))
      (PP (IN:[513..516] for)
        (NP (DT:[517..520] the) (NN:[521..527] enzyme))))
    (VP (VBD:[528..531] was)
      (VP (VBN:[532..537] found)
        (NP-4 (-NONE-:[537..537] *))
        (PP-LOC
          (PP (IN:[538..540] in)
            (NP
              (NP
                (ADJP (JJ:[542..547] small)
                  (PRN (-LRB-:[548..549] -LRB-)
                    (NP
                      (NP (CD:[549..551] 15))
                      (PP (HYPH:[551..552] -)
                        (NP (CD:[552..554] 18) (NNS:[555..562] microns))))
                    (-RRB-:[562..563] -RRB-)))
                (NML-3 (-NONE-:[563..563] *P*)))
              (CC:[564..567] and)
              (NP
                (ADJP (JJ:[568..573] large)
                  (PRN (-LRB-:[574..575] -LRB-)
                    (NP
                      (NP (CD:[575..577] 18))
                      (PP (HYPH:[577..578] -)
                        (NP (CD:[578..580] 45) (NNS:[581..588] microns))))
                    (-RRB-:[588..589] -RRB-)))
                (NML-3 (NNS:[590..595] cells)))))
          (CONJP (RB:[596..598] as) (RB:[599..603] well) (IN:[604..606] as))
          (PP (IN:[607..609] in)
            (NP
              (NP
                (ADJP (AFX:[610..613] non) (HYPH:[613..614] -)
                      (JJ:[614..620] luteal))
                (NNS:[622..627] cells))
              (,:[627..628] ,)
              (NP (JJ:[629..638] arteriole) (JJ:[639..645] smooth)
                  (NN:[646..652] muscle))
              (CD:[653..656] and)
              (NP (NN:[657..668] endothelium)))))))
    (.:[668..669] .)))

;sentence 6 Span:670..798
;There was no consistent  difference between small and large luteal cells and
;luteal vs. non-luteal cells  in the immunostaining.
(SENT
  (S
    (NP-SBJ (EX:[670..675] There))
    (VP (VBD:[676..679] was)
      (NP-PRD
        (NP (DT:[680..682] no) (JJ:[683..693] consistent)
            (NN:[695..705] difference))
        (PP (IN:[706..713] between)
          (NP
            (NP
              (NP (JJ:[714..719] small)
                (NML-1 (-NONE-:[719..719] *P*)))
              (CC:[720..723] and)
              (NP (JJ:[724..729] large)
                (NML-1 (JJ:[730..736] luteal) (NNS:[737..742] cells))))
            (CC:[743..746] and)
            (NP
              (NP (JJ:[747..753] luteal)
                (NML-2 (-NONE-:[753..753] *P*)))
              (FW:[754..757] vs.)
              (NP
                (ADJP (AFX:[758..761] non) (HYPH:[761..762] -)
                      (JJ:[762..768] luteal))
                (NML-2 (NNS:[769..774] cells)))))))
      (PP-LOC (IN:[776..778] in)
        (NP (DT:[779..782] the) (NN:[783..797] immunostaining))))
    (.:[797..798] .)))

;sentence 7 Span:799..916
;Vascular smooth muscle and endothelial cells, on the  other hand, contained
;less immunostaining than the other cells.
(SENT
  (S
    (NP-SBJ
      (NP
        (NP (JJ:[799..807] Vascular)
          (NML (JJ:[808..814] smooth) (NN:[815..821] muscle))
          (NML-1 (-NONE-:[821..821] *P*)))
        (CC:[822..825] and)
        (NP (JJ:[826..837] endothelial)
          (NML-1 (NNS:[838..843] cells))))
      (,:[843..844] ,)
      (PP (IN:[845..847] on)
        (NP (DT:[848..851] the) (JJ:[853..858] other) (NN:[859..863] hand))))
    (,:[863..864] ,)
    (VP (VBD:[865..874] contained)
      (NP
        (NP (JJR:[875..879] less) (NN:[880..894] immunostaining))
        (PP (IN:[895..899] than)
          (NP (DT:[900..903] the) (JJ:[904..909] other) (NNS:[910..915] cells)))))
    (.:[915..916] .)))

;sentence 8 Span:917..1038
;Contrary to  wide-spread distribution of PGI2 synthase, specific PGI2 binding
;sites were only  found in the luteal cells.
;[958..971]:cyp450:"PGI2 synthase"
;[982..986]:substance:"PGI2"
(SENT
  (S
    (ADVP (RB:[917..925] Contrary)
      (PP (TO:[926..928] to)
        (NP
          (NP
            (ADJP (RB:[930..934] wide) (HYPH:[934..935] -)
                  (VBN:[935..941] spread))
            (NN:[942..954] distribution))
          (PP (IN:[955..957] of)
            (NP (NN:[958..962] PGI2) (NN:[963..971] synthase))))))
    (,:[971..972] ,)
    (NP-SBJ-1 (JJ:[973..981] specific) (NN:[982..986] PGI2)
              (NN:[987..994] binding) (NNS:[995..1000] sites))
    (VP (VBD:[1001..1005] were)
      (ADVP (RB:[1006..1010] only))
      (VP (VBN:[1012..1017] found)
        (NP-1 (-NONE-:[1017..1017] *))
        (PP-LOC (IN:[1018..1020] in)
          (NP (DT:[1021..1024] the) (JJ:[1025..1031] luteal)
              (NNS:[1032..1037] cells)))))
    (.:[1037..1038] .)))

;sentence 9 Span:1039..1175
;On a per cell basis, large luteal cells contained  more sites than small
;luteal cells and vice versa when expressed per unit cell  area.
(SENT
  (S
    (PP-MNR (IN:[1039..1041] On)
      (NP (DT:[1042..1043] a)
        (PP (IN:[1044..1047] per)
          (NP (NN:[1048..1052] cell)))
        (NN:[1053..1058] basis)))
    (,:[1058..1059] ,)
    (NP-SBJ (JJ:[1060..1065] large) (JJ:[1066..1072] luteal)
            (NNS:[1073..1078] cells))
    (VP (VBD:[1079..1088] contained)
      (NP
        (NP
          (NP (NN:[1090..1094] more) (NNS:[1095..1100] sites))
          (PP (IN:[1101..1105] than)
            (NP (JJ:[1106..1111] small) (JJ:[1112..1118] luteal)
                (NNS:[1119..1124] cells))))
        (CC:[1125..1128] and)
        (NP (NN:[1129..1133] vice) (NN:[1134..1139] versa)))
      (SBAR-TMP
        (WHADVP-2 (WRB:[1140..1144] when))
        (S
          (NP-SBJ-1 (-NONE-:[1144..1144] *))
          (VP (VBN:[1145..1154] expressed)
            (NP-1 (-NONE-:[1154..1154] *))
            (PP (IN:[1155..1158] per)
              (NP
                (NML (NN:[1159..1163] unit) (NN:[1164..1168] cell))
                (NN:[1170..1174] area)))
            (ADVP-2 (-NONE-:[1174..1174] *T*))))))
    (.:[1174..1175] .)))

;sentence 10 Span:1176..1397
;The [3H]PGI2 binding to the luteal cells was time and temperature  dependent
;and was inhibited by excess unlabeled PGI2 but not by its metabolite, 
;6-keto-PGF1 alpha or other eicosanoids which bind to their own receptors.
;[1180..1188]:substance:"[3H]PGI2"
;[1291..1295]:substance:"PGI2"
;[1311..1321]:substance:"metabolite"
;[1324..1341]:substance:"6-keto-PGF1 alpha"
;[1351..1362]:substance:"eicosanoids"
;[1387..1396]:substance:"receptors"
(SENT
  (S
    (NP-SBJ-3
      (NP (DT:[1176..1179] The) (NN:[1180..1188] -LSB-3H-RSB-PGI2)
          (VBG:[1189..1196] binding))
      (PP (TO:[1197..1199] to)
        (NP (DT:[1200..1203] the) (JJ:[1204..1210] luteal)
            (NNS:[1211..1216] cells))))
    (VP
      (VP (VBD:[1217..1220] was)
        (ADJP-PRD
          (ADJP (NN:[1221..1225] time)
            (ADJP-2 (-NONE-:[1225..1225] *P*)))
          (CC:[1226..1229] and)
          (ADJP (NN:[1230..1241] temperature)
            (ADJP-2 (JJ:[1243..1252] dependent)))))
      (CC:[1253..1256] and)
      (VP (VBD:[1257..1260] was)
        (VP
          (VP (VBN:[1261..1270] inhibited)
            (NP-3 (-NONE-:[1270..1270] *))
            (PP-LGS=4 (IN:[1271..1273] by)
              (NP (JJ:[1274..1280] excess) (JJ:[1281..1290] unlabeled)
                  (NN:[1291..1295] PGI2))))
          (CC:[1296..1299] but) (RB:[1300..1303] not)
          (VP
            (PP-LGS=4 (IN:[1304..1306] by)
              (NP
                (NP
                  (NP (PRP$:[1307..1310] its) (NN:[1311..1321] metabolite))
                  (,:[1321..1322] ,)
                  (NP (NN:[1324..1335] 6-keto-PGF1) (SYM:[1336..1341] alpha)))
                (CC:[1342..1344] or)
                (NP
                  (NP (JJ:[1345..1350] other) (NNS:[1351..1362] eicosanoids))
                  (SBAR
                    (WHNP-1 (WDT:[1363..1368] which))
                    (S
                      (NP-SBJ-1 (-NONE-:[1368..1368] *T*))
                      (VP (VBP:[1369..1373] bind)
                        (PP-CLR (TO:[1374..1376] to)
                          (NP (PRP$:[1377..1382] their) (JJ:[1383..1386] own)
                              (NNS:[1387..1396] receptors)))))))))))))
    (.:[1396..1397] .)))

;sentence 11 Span:1398..1628
;In  conclusion, while PGI2 synthase is widely distributed among different
;cell types  in bovine corpora lutea, specific binding sites which may mediate
;luteotropic  actions of PGI2 are only present in small and large luteal
;cells.
;[1420..1433]:cyp450:"PGI2 synthase"
;[1574..1578]:substance:"PGI2"
(SENT
  (S
    (PP (IN:[1398..1400] In)
      (NP (NN:[1402..1412] conclusion)))
    (,:[1412..1413] ,)
    (SBAR-ADV (IN:[1414..1419] while)
      (S
        (NP-SBJ (NN:[1420..1424] PGI2) (NN:[1425..1433] synthase))
        (VP (VBZ:[1434..1436] is)
          (ADJP-PRD
            (ADVP (RB:[1437..1443] widely))
            (JJ:[1444..1455] distributed)
            (PP (IN:[1456..1461] among)
              (NP (JJ:[1462..1471] different) (NN:[1472..1476] cell)
                  (NNS:[1477..1482] types))))
          (PP-LOC (IN:[1484..1486] in)
            (NP (JJ:[1487..1493] bovine) (FW:[1494..1501] corpora)
                (FW:[1502..1507] lutea))))))
    (,:[1507..1508] ,)
    (NP-SBJ
      (NP (JJ:[1509..1517] specific) (NN:[1518..1525] binding)
          (NNS:[1526..1531] sites))
      (SBAR
        (WHNP-2 (WDT:[1532..1537] which))
        (S
          (NP-SBJ-2 (-NONE-:[1537..1537] *T*))
          (VP (MD:[1538..1541] may)
            (VP (VB:[1542..1549] mediate)
              (NP
                (NP (JJ:[1550..1561] luteotropic) (NNS:[1563..1570] actions))
                (PP (IN:[1571..1573] of)
                  (NP (NN:[1574..1578] PGI2)))))))))
    (VP (VBP:[1579..1582] are)
      (ADJP-PRD (RB:[1583..1587] only) (JJ:[1588..1595] present)
        (PP-LOC (IN:[1596..1598] in)
          (NP
            (NP (JJ:[1599..1604] small)
              (NML-1 (-NONE-:[1604..1604] *P*)))
            (CC:[1605..1608] and)
            (NP (JJ:[1609..1614] large)
              (NML-1 (JJ:[1615..1621] luteal) (NNS:[1622..1627] cells)))))))
    (.:[1627..1628] .)))

;section 12 Span:1632..1675
;PMID: 2115851 [PubMed - indexed for MEDLINE
(SEC
  (FRAG (NNP:[1632..1636] PMID) (::[1636..1637] :) (CD:[1638..1645] 2115851)
        (-LRB-:[1646..1647] -LSB-) (NNP:[1647..1653] PubMed) (::[1654..1655] -)
        (NN:[1656..1663] indexed) (IN:[1664..1667] for)
        (NNP:[1668..1675] MEDLINE)))
;ERROR_Orphan Text from EOF Tree File[1675..EOF] ]

(ORPH -RSB-)
